Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Kessler

Showing results (481-490 of 524) with videos related to

Pageof 53
Sort By:
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
ESMO Open|April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialT Powles, M Burotto, B Escudier, et al.
JMIR Research Protocols|November 17, 2018
Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled TrialKerri M Winters-Stone, Stacey A Kenfield, Erin L Van Blarigan, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2016
Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in miceJonathan M Eby, Levi Barse, Steven W Henning, et al.
Brain, Behavior, and Immunity|December 21, 2024
Protective effects of Mycobacterium vaccae ATCC 15483 against "Western"-style diet-induced weight gain and visceral adiposity in adolescent male miceLuke W Desmond, Lamya'a M Dawud, Lyanna R Kessler, et al.
Nature|May 29, 2020
The stepwise assembly of the neonatal virome is modulated by breastfeedingGuanxiang Liang, Chunyu Zhao, Huanjia Zhang, et al.
Psychological Medicine|February 27, 2008
Mental disorders among persons with arthritis: results from the World Mental Health SurveysY He, M Zhang, E H B Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trialR J Motzer, B Escudier, M Burotto, et al.
Gastrointestinal Endoscopy|January 27, 2019
A phase III, multicenter, prospective, single-blinded, noninferiority, randomized controlled trial on the performance of a novel esophageal stent with an antireflux valve (with video)Kulwinder S Dua, John M DeWitt, William R Kessler, et al.
Pageof 53

Showing results (481-490 of 524) with videos related to

Sort By:
Pageof 53
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
ESMO Open|April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialT Powles, M Burotto, B Escudier, et al.
JMIR Research Protocols|November 17, 2018
Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled TrialKerri M Winters-Stone, Stacey A Kenfield, Erin L Van Blarigan, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2016
Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in miceJonathan M Eby, Levi Barse, Steven W Henning, et al.
Brain, Behavior, and Immunity|December 21, 2024
Protective effects of Mycobacterium vaccae ATCC 15483 against "Western"-style diet-induced weight gain and visceral adiposity in adolescent male miceLuke W Desmond, Lamya'a M Dawud, Lyanna R Kessler, et al.
Nature|May 29, 2020
The stepwise assembly of the neonatal virome is modulated by breastfeedingGuanxiang Liang, Chunyu Zhao, Huanjia Zhang, et al.
Psychological Medicine|February 27, 2008
Mental disorders among persons with arthritis: results from the World Mental Health SurveysY He, M Zhang, E H B Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trialR J Motzer, B Escudier, M Burotto, et al.
Gastrointestinal Endoscopy|January 27, 2019
A phase III, multicenter, prospective, single-blinded, noninferiority, randomized controlled trial on the performance of a novel esophageal stent with an antireflux valve (with video)Kulwinder S Dua, John M DeWitt, William R Kessler, et al.
Pageof 53